Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Misses Expectations By $0.10 EPS

Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10), Zacks reports. During the same quarter last year, the business posted ($0.26) EPS.

Autolus Therapeutics Stock Down 1.2 %

NASDAQ:AUTL opened at $3.29 on Thursday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $3.95 and a two-hundred day moving average price of $4.00. Autolus Therapeutics has a 1 year low of $3.06 and a 1 year high of $7.45. The stock has a market cap of $875.44 million, a price-to-earnings ratio of -2.72 and a beta of 2.04.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.